Pfizer Inc. (NYSE:PFE) Shares Sold by Argent Trust Co

Argent Trust Co lowered its holdings in Pfizer Inc. (NYSE:PFE) by 11.7% during the first quarter, Holdings Channel reports. The fund owned 227,277 shares of the biopharmaceutical company’s stock after selling 29,994 shares during the quarter. Argent Trust Co’s holdings in Pfizer were worth $8,234,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in PFE. North American Management Corp grew its position in Pfizer by 4.0% during the first quarter. North American Management Corp now owns 186,886 shares of the biopharmaceutical company’s stock valued at $6,771,000 after buying an additional 7,122 shares during the period. Jones Financial Companies Lllp grew its position in Pfizer by 2.0% during the first quarter. Jones Financial Companies Lllp now owns 358,298 shares of the biopharmaceutical company’s stock valued at $12,981,000 after buying an additional 7,005 shares during the period. Wellington Shields Capital Management LLC grew its position in Pfizer by 7.6% during the fourth quarter. Wellington Shields Capital Management LLC now owns 104,766 shares of the biopharmaceutical company’s stock valued at $3,856,000 after buying an additional 7,405 shares during the period. Kanawha Capital Management LLC grew its position in Pfizer by 2.5% during the first quarter. Kanawha Capital Management LLC now owns 233,336 shares of the biopharmaceutical company’s stock valued at $8,454,000 after buying an additional 5,682 shares during the period. Finally, Roosevelt Investment Group LLC grew its position in Pfizer by 11.8% during the first quarter. Roosevelt Investment Group LLC now owns 91,124 shares of the biopharmaceutical company’s stock valued at $3,301,000 after buying an additional 9,625 shares during the period. Hedge funds and other institutional investors own 64.22% of the company’s stock.

In other Pfizer news, SVP Jennifer B. Damico sold 2,500 shares of Pfizer stock in a transaction dated Wednesday, May 5th. The shares were sold at an average price of $40.82, for a total transaction of $102,050.00. Following the completion of the sale, the senior vice president now directly owns 13,748 shares in the company, valued at $561,193.36. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.05% of the stock is owned by company insiders.

Several analysts recently commented on the stock. Berenberg Bank restated a “neutral” rating and set a $38.00 price target on shares of Pfizer in a research report on Tuesday, March 23rd. Morgan Stanley increased their price objective on shares of Pfizer from $38.00 to $42.00 and gave the company an “equal weight” rating in a report on Monday, May 10th. Barclays increased their price objective on shares of Pfizer from $37.00 to $40.00 and gave the company an “equal weight” rating in a report on Wednesday, May 5th. The Goldman Sachs Group set a $45.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a report on Monday, May 24th. Finally, Royal Bank of Canada started coverage on shares of Pfizer in a report on Wednesday, April 7th. They set a “sector perform” rating and a $42.00 price objective on the stock. Twelve investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $39.73.

PFE stock traded down $0.66 during trading on Friday, reaching $40.02. 527,527 shares of the stock were exchanged, compared to its average volume of 30,701,137. The company has a quick ratio of 1.16, a current ratio of 1.48 and a debt-to-equity ratio of 0.51. The stock has a 50 day simple moving average of $38.76. Pfizer Inc. has a 1 year low of $31.61 and a 1 year high of $43.08. The stock has a market cap of $224.02 billion, a price-to-earnings ratio of 20.76, a price-to-earnings-growth ratio of 1.42 and a beta of 0.74.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 4th. The biopharmaceutical company reported $0.93 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.15. Pfizer had a net margin of 22.09% and a return on equity of 24.55%. The company had revenue of $14.58 billion for the quarter, compared to the consensus estimate of $13.41 billion. During the same period in the previous year, the firm earned $0.80 earnings per share. Pfizer’s quarterly revenue was up 44.6% compared to the same quarter last year. Sell-side analysts expect that Pfizer Inc. will post 3.69 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, June 4th. Shareholders of record on Friday, May 7th were given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.90%. The ex-dividend date was Thursday, May 6th. Pfizer’s dividend payout ratio is presently 70.27%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.

Featured Story: Non-Fungible Token (NFT)

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.